CDH2 and glioma: showed that bevacizumab induces PMT in glioma cells characterized by decreased E‐cadherin along with increased N‐cadherin and vimentin.[109] Piao and colleagues performed gene expression analysis of bevacizumab‐resistant cells and found that these cells are associated with mesenchymal‐like characteristics[110] along with increased invasion, migration, and pro‐inflammatory cytokines expression.